ValuEngine lowered shares of Neoleukin Therapeutics (NASDAQ:NLTX) from a hold rating to a sell rating in a report issued on Tuesday morning, ValuEngine reports.

Shares of NASDAQ NLTX opened at $5.23 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 26.35 and a current ratio of 26.35. Neoleukin Therapeutics has a one year low of $2.00 and a one year high of $6.59. The company’s fifty day moving average price is $3.39.

Neoleukin Therapeutics (NASDAQ:NLTX) last announced its quarterly earnings data on Wednesday, November 13th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.40).

Several hedge funds and other institutional investors have recently bought and sold shares of NLTX. State Street Corp bought a new stake in shares of Neoleukin Therapeutics in the third quarter valued at approximately $35,000. Virtu Financial LLC bought a new stake in Neoleukin Therapeutics during the 3rd quarter valued at $57,000. California Public Employees Retirement System bought a new stake in Neoleukin Therapeutics during the 3rd quarter valued at $162,000. Finally, Millennium Management LLC bought a new stake in Neoleukin Therapeutics during the 3rd quarter valued at $1,166,000. 66.90% of the stock is currently owned by institutional investors.

Neoleukin Therapeutics Company Profile

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy.

Featured Article: How much can an individual set aside as a catch-up contribution?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.